CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alterola Biotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alterola Biotech Inc
47 Hamilton Squar
Phone: (909) 584-5853p:909 584-5853 BIRKENHEAD, CA  CH415AR  United Kingdom Ticker: ABTIABTI
On September 24, 2024, the Board of directors of Alterola Biotech, Inc. determined, upon the recommendation of the company’s management, and in consultation with the Company’s independent registered public accounting firm, that the company should restate its previously issued financial statements for quarter ended June 30, 2024 to correct the accounting in its unaudited balance sheets for said quarter. The restatement relates to an error in the consolidation of the company’s subsidiaries. The company does not believe that there is a material impact to the financial statements and the error was an oversight that occurred as part of its internal reorganization with a newly formed subsidiary.
Business Summary
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20243/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Financial Officer Timothy P.Rogers 60 1/1/2022 12/2/2020
Chief Executive Officer, Director David J.Hitchcock 60 10/7/2022 5/17/2022
Chief Operating Officer, Director ColinStott 57 6/21/2021 6/21/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
ABTI
ABTI Pharma Ltd.
ALTA
Jedediah Resources Corp

General Information
Number of Employees: 1 (As of 3/31/2024)
Outstanding Shares: 1,459,502,018 (As of 8/14/2024)
Shareholders: 139
Stock Exchange: OTC


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024